Esophageal Cancer - Pipeline Review, H1 2016

Description: Esophageal Cancer - Pipeline Review, H1 2016

Summary

‘Esophageal Cancer - Pipeline Review, H1 2016’, provides an overview of the Esophageal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Esophageal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer
- The report reviews pipeline therapeutics for Esophageal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Esophageal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Esophageal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Esophageal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Tables
List of Figures
Introduction
Report Coverage
Esophageal Cancer Overview
Therapeutics Development
Pipeline Products for Esophageal Cancer - Overview
Pipeline Products for Esophageal Cancer - Comparative Analysis
Esophageal Cancer - Therapeutics under Development by Companies
Esophageal Cancer - Therapeutics under Investigation by Universities/Institutes
Esophageal Cancer - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Esophageal Cancer - Products under Development by Companies
Esophageal Cancer - Products under Investigation by Universities/Institutes
Esophageal Cancer - Companies Involved in Therapeutics Development
Adaptimmune Therapeutics Plc
Advantagene, Inc.
Advaxis, Inc.
Advenchen Laboratories, LLC
Almac Discovery Limited
Amgen Inc.
ArQule, Inc.
Array BioPharma Inc.
Aslan Pharmaceuticals Pte. Ltd.
ATLAB Pharma SAS
Bayer AG
Sihuan Pharmaceutical Holdings Group Ltd.
Spectrum Pharmaceuticals, Inc.
Symphogen A/S
Synta Pharmaceuticals Corp.
Taiho Pharmaceutical Co., Ltd.
Taiwan Liposome Company, Ltd.
Takara Bio Inc.
tella Inc
TG Therapeutics, Inc.
Transgene Biotek Limited
VioQuest Pharmaceuticals, Inc.
Virocan Therapeutics Private Limited
Esophageal Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(tipiracil hydrochloride + trifluridine) - Drug Profile
1-BB1 - Drug Profile
ADXS-HER2 - Drug Profile
afatinib dimaleate - Drug Profile
AL-3818 - Drug Profile
ALM-301 - Drug Profile
alpelisib - Drug Profile
AMG-337 - Drug Profile
apatinib - Drug Profile
ATL-101 - Drug Profile
binimetinib - Drug Profile
CDX-1401 - Drug Profile
Cellular Immunotherapy for Oncology - Drug Profile
Cellular Immunotherapy for Oncology - Drug Profile
Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology - Drug Profile
Cellular Immunotherapy to Target NY-ESO-1 for Oncology - Drug Profile
cetuximab biobetter - Drug Profile
CGX-1321 - Drug Profile
CRLX-101 - Drug Profile
CYC-140 - Drug Profile
Cytokine Induced Killer Cells + Dendritic Cells - Drug Profile
dacomitinib - Drug Profile
DKN-01 - Drug Profile
donafenib - Drug Profile
durvalumab - Drug Profile
elgemtumab - Drug Profile
erdafitinib - Drug Profile
futuximab - Drug Profile
ganetespib - Drug Profile
gedatolisib - Drug Profile
Gene Therapy for Esophageal Cancer - Drug Profile
Gene Therapy to Activate p53 for Oncology - Drug Profile
GSK-3377794 - Drug Profile
HMPL-309 - Drug Profile
I131-CLR1404 - Drug Profile
icotinib hydrochloride - Drug Profile
IMF-001 - Drug Profile
IMGN-289 - Drug Profile
KML-001 - Drug Profile
margetuximab - Drug Profile
MBP-426 - Drug Profile
MMD-37K - Drug Profile
Monoclonal Antibodies to Inhibit PD-L2 for Esophageal Cancer - Drug Profile
Products under Investigation by Universities/Institutes, H1 2016
Esophageal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2016
Esophageal Cancer - Pipeline by Advantagene, Inc., H1 2016
Esophageal Cancer - Pipeline by Advaxis, Inc., H1 2016
Esophageal Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016
Esophageal Cancer - Pipeline by Almac Discovery Limited, H1 2016
Esophageal Cancer - Pipeline by Amgen Inc., H1 2016
Esophageal Cancer - Pipeline by ArQule, Inc., H1 2016
Esophageal Cancer - Pipeline by Array BioPharma Inc., H1 2016
Esophageal Cancer - Pipeline by Asian Pharmaceuticals Pte. Ltd., H1 2016
Esophageal Cancer - Pipeline by ATLAB Pharma SAS, H1 2016
Esophageal Cancer - Pipeline by Bayer AG, H1 2016
Esophageal Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H1 2016
Esophageal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016
Esophageal Cancer - Pipeline by Celgene Corporation, H1 2016
Esophageal Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016
Esophageal Cancer - Pipeline by Cellectar Biosciences, Inc., H1 2016
Esophageal Cancer - Pipeline by Cerulean Pharma, Inc., H1 2016
Esophageal Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016
Esophageal Cancer - Pipeline by Genmab A/S, H1 2016
Esophageal Cancer - Pipeline by Glycotope GmbH, H1 2016
Esophageal Cancer - Pipeline by Hutchison MediPharma Limited, H1 2016
Esophageal Cancer - Pipeline by Ignyta, Inc., H1 2016
Esophageal Cancer - Pipeline by ImmunoFrontier, Inc., H1 2016
Esophageal Cancer - Pipeline by ImmunoGen, Inc., H1 2016
Esophageal Cancer - Pipeline by Immunomedics, Inc., H1 2016
Esophageal Cancer - Pipeline by Johnson & Johnson, H1 2016
Esophageal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
Esophageal Cancer - Pipeline by Komipharm International Co., Ltd., H1 2016
Esophageal Cancer - Pipeline by MacroGenics, Inc., H1 2016
Esophageal Cancer - Pipeline by Mebiopharm Co., Ltd., H1 2016
Esophageal Cancer - Pipeline by MedImmune, LLC, H1 2016
Esophageal Cancer - Pipeline by Merck & Co., Inc., H1 2016
Esophageal Cancer - Pipeline by Novartis AG, H1 2016
Esophageal Cancer - Pipeline by Omeros Corporation, H1 2016
Esophageal Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2016
Esophageal Cancer - Pipeline by Oncolys BioPharma Inc., H1 2016
Esophageal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
Esophageal Cancer - Pipeline by Pfizer Inc., H1 2016
Esophageal Cancer - Pipeline by Proteo, Inc., H1 2016
Esophageal Cancer - Pipeline by Puma Biotechnology, Inc., H1 2016
Esophageal Cancer - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H1 2016
Esophageal Cancer - Pipeline by Shionogi & Co., Ltd., H1 2016
Esophageal Cancer - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016
Esophageal Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016
Esophageal Cancer - Pipeline by Symphogen A/S, H1 2016
Esophageal Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016
Esophageal Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016
Esophageal Cancer - Pipeline by Taiwan Liposome Company, Ltd., H1 2016
Esophageal Cancer - Pipeline by Takara Bio Inc., H1 2016
Esophageal Cancer - Pipeline by tella Inc, H1 2016
Esophageal Cancer - Pipeline by TG Therapeutics, Inc., H1 2016
Esophageal Cancer - Pipeline by Transgene Biotek Limited, H1 2016
Esophageal Cancer - Pipeline by VioQuest Pharmaceuticals, Inc., H1 2016
Esophageal Cancer - Pipeline by Virocan Therapeutics Private Limited, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Esophageal Cancer Therapeutics - Recent Pipeline Updates, H1 2016
Esophageal Cancer - Dormant Projects, H1 2016
Esophageal Cancer - Dormant Projects (Contd..1), H1 2016
Esophageal Cancer - Dormant Projects (Contd..2), H1 2016
Esophageal Cancer - Dormant Projects (Contd..3), H1 2016
Esophageal Cancer - Dormant Projects (Contd..4), H1 2016
Esophageal Cancer - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Esophageal Cancer, H1 2016
Number of Products under Development for Esophageal Cancer - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Top 10 Routes of Administration, H1 2016
Number of Products by Stage and Top 10 Routes of Administration, H1 2016
Number of Products by Top 10 Molecule Types, H1 2016
Number of Products by Stage and Top 10 Molecule Types, H1 2016

Ordering:

Order Online - http://www.researchandmarkets.com/reports/3693091/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
RESEARCH AND MARKETS

Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Esophageal Cancer - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3693091/
Office Code: SCD2LPTV

Product Formats
Please select the product formats and quantity you require:

Quantity
- Electronic (PDF) - Single User: ☐ USD 2000
- Electronic (PDF) - Site License: ☐ USD 4000
- Electronic (PDF) - Enterprisewide: ☐ USD 6000

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:                          Mr ☐  Mrs ☐  Dr ☐  Miss ☐  Ms ☐  Prof ☐
First Name:                        ________________________________  Last Name: ________________________________
Email Address: *                      ________________________________
Job Title:                          ________________________________
Organisation:                      ________________________________
Address:                           ________________________________
City:                              ________________________________
Postal / Zip Code:                 ________________________________
Country:                           ________________________________
Phone Number:                      ________________________________
Fax Number:                        ________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World